Why the study?
Does adding cilostazol to aspirin and clopidogrel reduce platelet activation in patients with coronary stenting?
Does adding cilostazol to aspirin and clopidogrel reduce platelet activation in patients with coronary stenting?
Adding cilostazol to conventional dual antiplatelet therapy significantly suppresses platelet P-selectin expression in coronary stenting patients, particularly those with relatively high baseline platelet activity.
No takes yet. Share an insight, caveat, or question.
May support cilostazol for platelet suppression in stenting; hypothesis-generating and requires randomized outcome trials.
Ahn et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: